BIFS: Safety Follow-up Study in Subjects With Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms

Sponsor
Allergan (Industry)
Overall Status
Recruiting
CT.gov ID
NCT00443274
Collaborator
(none)
56,460
1
200.6
281.4

Study Details

Study Description

Brief Summary

Ten year safety study examining rates of rare adverse events, child bearing issues, effects of mammography, MRI compliance and results, and long-term benefit of silicone-filled breast implants.

Condition or Disease Intervention/Treatment Phase
  • Other: NBIR - US National Breast Implant Registry
  • Device: 410 Arm
  • Device: BIFs - Breast Implant Follow-Up Study

Study Design

Study Type:
Observational
Anticipated Enrollment :
56460 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Breast Implant Follow-up Study: A Long-term Observational Study of the Safety of Allergan Silicone Gel-filled Breast Implants as Compared Both to Saline-filled Breast Implants and to National Norms (410-arm)
Actual Study Start Date :
Nov 1, 2006
Anticipated Primary Completion Date :
Jul 21, 2023
Anticipated Study Completion Date :
Jul 21, 2023

Outcome Measures

Primary Outcome Measures

  1. Risk rates of adverse events of high clinical interest (eg, cancers, neurological diseases, connective tissue diseases) assessed by the investigator [10 Years]

  2. Risk rates of common complications of breast surgery (eg, capsular contracture, implant rupture/deflation) assessed by the subject and investigator [10 Years]

  3. Re-operations [10 Years]

    Rates of reoperation reported by subjects and by investigators at office visits

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
Female
Accepts Healthy Volunteers:
No
Inclusion Criteria:

Screening Criteria

  1. Female

  2. age 18 years or older who is a candidate for breast reconstruction (primary or revision) with Allergan silicone implants or saline breast implants (controls) OR

  3. age 22 or older who is a candidate for breast augmentation (primary or revision) with Allergan silicone implants or saline breast implants (controls)

  4. Exhibit fluency and literacy in English or Spanish

Enrollment Criteria

  1. Have satisfied all the inclusion and none of the exclusion criteria

  2. Have completed the implant surgery

  3. Have only one breast implant or have matching breast implants (i.e., both Round Responsive, both Style 410, or both saline) following their qualifying surgery. In the case of silicone, the device(s) must be manufactured by Allergan.

  4. Are free of all target diseases at baseline (410 arm only)

  5. Have signed the informed consent form, documenting agreement to participate in all required follow-up interviews by internet, phone, or mail and authorizing health care providers to release medical records to study personnel, and have completed the baseline questionnaire prior to implant surgery (prospectively enrolled subjects)

For retrospectively enrolled subjects into the 410 arm, in addition to the above, these criteria also apply:

  1. Received 1 or 2 Style 410 implants between 2015 and 2019

  2. Willing to complete baseline questionnaire at time of enrollment

Continuation Criteria (BIFS Arm Only)

  1. Have completed baseline and years 1, 2, 3 and 4 follow-up questionnaires available (including the Satisfaction with Breasts and Psychosocial Well-Being modules of the BREAST-Q)

  2. Met all enrollment criteria, specifically the minimum age requirements for silicone implants (18 or older for reconstruction subjects and 22 or older for augmentation subjects), and were free of all target diseases at baseline

  3. Were enrolled at a site that was selected in the cluster sampling to continue in the BIFS arm

Exclusion Criteria:
  1. Are transgender

  2. If a saline implant subject, have a current or past unilateral or bilateral silicone gelfilled breast implant

  3. Investigator decision that subject is not a suitable candidate for a long-term observational study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Southwest Plastic Surgery /ID# 240510 El Paso Texas United States 79925-7618

Sponsors and Collaborators

  • Allergan

Investigators

  • Study Director: ALLERGAN INC., Allergan

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Allergan
ClinicalTrials.gov Identifier:
NCT00443274
Other Study ID Numbers:
  • BIFS001
First Posted:
Mar 5, 2007
Last Update Posted:
Nov 8, 2021
Last Verified:
Nov 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Nov 8, 2021